Faith in Action Campaign Launches to Promote Brain Health Among Black Americans

In partnership with The Alter Program and national faith leaders, UsAgainstAlzheimer’s is launching Faith in Action, an initiative bringing free culturally tailored brain health information and resources to the pews of more than 30 churches, with an emphasis on Georgia.

Giving Tuesday is on November 29th

On Giving Tuesday remember that your contributions matter in the fight to end # Alzheimer's disease for patients and their loved ones.

The Brain Health Academy

Free, evidence-based courses to equip healthcare and wellness providers with the knowledge and resources to help people reduce the risk of dementia and Alzheimer’s.

Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

Alzheimer’s patients and their loved ones have new reason for hope following Phase 3 trial results of lecanemab released by Eisai Tuesday night. The results showed the drug reduced the progression of Alzheimer’s by 27 percent over 18 months, compared to placebo. Like other drugs in the same class, lecanemab is designed to slow the progression of Alzheimer’s disease by targeting amyloid plaque buildup in the brain.

Say Hello to BrainGuide

Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

New Survey: Three in Four in Alzheimer’s Community Want Medicare to Cover Alzheimer’s Treatments

A new A-LIST® survey of people with Alzheimer’s and Alzheimer’s caregivers shows that 75 percent want Medicare to cover new therapies—even after they are told that the drugs have a risk of side effects and still require confirmatory trials.

Faith in Action Campaign Launches to Promote Brain Health Among Black Americans

Giving Tuesday

The Brain Health Academy

Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

Say Hello to BrainGuide

Three in Four in Alzheimer’s Community Want Medicare to Cover Alzheimer’s Treatments

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is one of the most significant health and social economic crises of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • December 26, 2021

    Becerra: Federal Government to Make Alzheimer’s Prevention a National Priority

    UsAgainstAlzheimer’s applauded Health and Human Services Secretary Xavier Becerra, who announced on...

    Read more
  • December 22, 2021

    Letter to Becerra: Historic Medicare Premium Increase Must be Reversed Based on New Data

    UsAgainstAlzheimer’s, a patient advocacy group representing more than six million Alzheimer’s patients...

    Read more
  • December 20, 2021

    Dramatic Price Reduction for Aduhelm Gives Hope to Alzheimer’s Patients

    More patients will soon have access to Aduhelm, the only treatment on...

    Read more
  • December 17, 2021

    European Medicines Agency Blocks Treatment for Alzheimer’s Patients

    The European Medicines Agency (EMA) today delivered an unconscionable blow to Alzheimer’s...

    Read more
  • December 17, 2021

    Read Full Article

    Early Descriptions of Family Caregivers' Experiences With Unexpected Lucidity

    Innovations in Aging, December 2021

    Read more
  • December 16, 2021

    UsAgainstAlzheimer’s Applauds Biogen for Speeding up Follow-up Trials for Aduhelm

    The company that manufactures Aduhelm, the only treatment on the market that...

    Read more

Reports

  • Resources
    Us Against Alzheimer's 2021 Annual Report

    2021 Annual Report

    With breakthroughs in treatment, a remarkable step forward in prevention, and a new initiative to raise public awareness of the importance of brain health, many efforts were led by UsAgainstAlzheimer’s...

  • Resources
    A-List 2017-2022 surveys

    A-List What Matters Most Surveys

    A-List 2017-2022 surveys, updated July 2022

  • Resources

    A-LIST Pulse of the Community - December 2021